Medtronic plc is an Irish company that develops medical therapies, with a market cap of $115 billion and revenue from four core segments. MDT stock has seen a 10.6% surge in the past year and a 11.9% increase year-to-date, outpacing the S&P 500. Analysts predict an EPS growth of 1.1% for the current year.

Medtronic received CE Mark approval for its insulin delivery system, leading to a 2.2% increase in shares. Analyst sentiment is a “Moderate Buy,” with a shift towards more bullish ratings recently. Mizuho Financial and Morgan Stanley raised their price targets for Medtronic, citing the company’s strong position in the medical technology sector.

The mean price target for Medtronic is $95.83, representing a 7.2% premium to current levels. The highest price target is $110, suggesting a potential 23.1% upside. Analysts remain constructive on Medtronic due to stable procedure volumes and spending trends in hospitals.

Read more at Yahoo Finance: Are Wall Street Analysts Bullish on Medtronic Stock?